Key result
Late intravenous thrombolysis yields ~45% higher odds of excellent functional outcome at 90 days.
Why the study?
Intravenous thrombolysis for acute ischaemic stroke may be beneficial up to 24 hours after onset, and new trial evidence warranted an updated synthesis of late-window alteplase and tenecteplase trials.
Does intravenous thrombolysis with alteplase or tenecteplase between 4.5 and 24 hours after stroke onset improve 90-day excellent functional outcome (mRS 0–1) in patients with acute ischaemic stroke?
Meta-Analysis (n=2,548)
Open-label or PROBE with blinded outcome assessment (majority), Double-blind (TIMELESS)
Randomised controlled trials included
Yes
Does intravenous thrombolysis with alteplase or tenecteplase between 4.5 and 24 hours after stroke onset improve 90-day excellent functional outcome (mRS 0–1) in patients with acute ischaemic stroke?
In patients with acute ischaemic stroke selected primarily by tissue mismatch imaging, intravenous thrombolysis with tenecteplase or alteplase between 4.5 and 24 hours after onset significantly increases the odds of achieving an excellent functional outcome at 90 days without increasing mortality, despite a higher rate of symptomatic intracranial haemorrhage.
Answers are grounded in this paper and cite their sources.
Supports IV thrombolysis up to 24 hours in mismatch-selected patients; extends randomized evidence beyond the 9-hour window.
Background Intravenous thrombolysis (IVT) for ischaemic stroke may be beneficial up to 24 hours after onset. This is an up-to-date meta-analysis of late window IVT trials, including alteplase and tenecteplase, in light of new evidence. Methods Aggregate data from randomised controlled trials (RCTs) in the 4.5–24-hour window, with patient-level data from one trial were included. Random effects meta-analysis was performed for excellent functional outcome (90-day modified Rankin Score (mRS) of 0–1) as the primary outcome. Secondary outcomes were early neurological improvement (ENI), good functional outcome (90-day mRS 0–2) and safety outcomes. Prespecified subgroup analyses were conducted by endovascular thrombectomy (EVT) being available/permitted and treatment agent. Results Eight RCTs with n=2548 patients (mean age 67.7 years, median National Institute of Health Stroke Scale 9.5) were included. All but one trial used tissue mismatch imaging for patient selection. IVT significantly increased the odds of achieving the primary outcome (90-day mRS 0–1) (OR, 1.45 (95% CI 1.23 to 1.72); p<0.0001). For secondary outcomes, ENI was increased (OR, 1.59 (95% CI 1.02 to 2.46); p=0.04) while good functional outcome was not (OR, 1.27 (95% CI 0.96 to 1.67); p=0.10). IVT increased the risk of symptomatic intracranial haemorrhage (3% vs 1.2%, OR 2.2 (95% CI 1.17 to 4.13); p=0.01), with no difference in 90-day mortality (10% vs 9.8%, OR 1.01 (95% CI 0.77 to 1.32); p=0.94) or poor functional outcome (OR, 0.91 (95% CI 0.72 to 1.14); p=0.40. Subgroup analyses did not demonstrate an interaction p<0.05 for the primary outcome. Discussion The current meta-analysis of late window IVT shows overall benefit on clinical outcomes between 4.5 and 24 hours after stroke onset, despite increase in intracranial haemorrhage. Subgroup analyses are underpowered and further data are needed to determine if there are clinically significant interactions by EVT status. PROSPERO registration number CRD420261356162.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a meta-analysis in Acute ischaemic stroke (n=2,548). Intravenous thrombolysis (tenecteplase or alteplase) vs. Standard medical care or placebo was evaluated on Excellent functional outcome (modified Rankin Scale score 0-1 at 90 days) (OR 1.45, 95% CI 1.23 to 1.72, p=<0.0001). Intravenous thrombolysis administered 4.5–24 hours after stroke onset increased 90-day excellent functional outcome.
Synapse has enriched 10 related papers. Consider them for comparative context: